# Friso MUM, the activity of a health supplement during pregnancy and lactation

Submission date	Recruitment status No longer recruiting	Prospectively registered		
19/12/2005		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
19/12/2005	Completed	[X] Results		
Last Edited	Condition category	Individual participant data		
07/01/2021	Mental and Behavioural Disorders			

### Plain English summary of protocol

Not provided at time of registration

# Contact information

#### Type(s)

Scientific

#### Contact name

Dr Saskia A van Goor

#### Contact details

University Medical Center Groningen
Department of Pathology and Laboratory Medicine
Postblok CMC-V-1 floor
P.O. Box 30001
Groningen
Netherlands
9700 RB
+31 (0)50 3610399
s.a.van.goor@lc.umcg.nl

# Additional identifiers

Protocol serial number N/A

# Study information

Scientific Title

The effect of high docosahexaenoic acid (DHA)-fish oil and arachidonic acid (AA) suppletion during pregnancy and lactation on long-chain polyunsaturated fatty acids (LCP) status of mother and child and on the neurological development of the baby

#### **Acronym**

MUM

#### **Study objectives**

Docosahexaenoic acid (DHA) and arachidonic acid (AA) during pregnancy shall lead to a better neurological development of the baby and possibly to better mood, cognitive functioning and sleeping rhythm of the mother.

#### Ethics approval required

Old ethics approval format

#### Ethics approval(s)

Received from the local medical ethics committee

#### Study design

Randomised double-blind, placebo controlled, parallel group trial

#### Primary study design

Interventional

#### Study type(s)

Treatment

## Health condition(s) or problem(s) studied

Developmental disorder

#### Interventions

Everybody receives a multivitamin supplement (designed for pregnant women). As well as this we compare placebo versus DHA versus DHA/AA.

#### **Intervention Type**

Drug

#### Phase

**Not Specified** 

#### Drug/device/biological/vaccine name(s)

Docosahexaenoic acid (DHA), arachidonic acid (AA)

#### Primary outcome(s)

Neurological development of the baby (Neurological Optimality Score and General Movements)

#### Key secondary outcome(s))

- 1. Mood, cognitive functioning and sleeping rhythm of the mother
- 2. LCP status in red blood cells of mother (16th and 36th week) and child (12 weeks after birth), umbilical cord, breast milk (2 and 12 weeks after birth)

#### Completion date

01/10/2007

# **Eligibility**

#### Key inclusion criteria

- 1. Apparently healthy pregnant women
- 2. Para 0 or 1
- 3. Inclusion should take place prior to the 16th week of pregnancy

## Participant type(s)

**Patient** 

## Healthy volunteers allowed

No

#### Age group

Adult

#### Sex

Female

#### Total final enrolment

119

#### Key exclusion criteria

- 1. Hyperemesis Gravidarum
- 2. Vegetarian or vegan
- 3. Pregnant with twins
- 4. Diabetes Mellitus type 1
- 5. Usage of health supplements with fatty acids, tryptophan or melatonin

#### Date of first enrolment

01/11/2004

#### Date of final enrolment

01/10/2007

# Locations

#### Countries of recruitment

Netherlands

Study participating centre
University Medical Center Groningen
Groningen
Netherlands
9700 RB

# Sponsor information

#### Organisation

Friesland Foods (The Netherlands)

#### **ROR**

https://ror.org/025mtxh67

# Funder(s)

## Funder type

Not defined

#### **Funder Name**

Not provided at time of registration

# **Results and Publications**

Individual participant data (IPD) sharing plan

## IPD sharing plan summary

Not provided at time of registration

# **Study outputs**

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	results	01/02/2009	07/01/2021	Yes	No